Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation (Q34313221)

1 August 2017

1 reference

title

Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation (English)

1 reference

1 August 2017

Serap Gur

1

1 reference

ORCID Public Data File 2021

Philip J. Kadowitz

series ordinal

2

object named as

Philip J Kadowitz

1 reference

1 August 2017

Wayne Jg Hellstrom

3

1 reference

1 August 2017

language of work or name

English

0 references

publication date

22 November 2012

1 reference

Expert Opinion on Drug Safety

1 August 2017

published in

1 reference

1 August 2017

volume

12

1 reference

1 August 2017

issue

1

1 reference

1 August 2017

page(s)

81-90

1 reference

Guide to drug therapy for lower urinary tract symptoms in patients with benign prostatic obstruction : implications for sexual dysfunction

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

Medical therapy for benign prostatic hyperplasia: sexual dysfunction and impact on quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

Persistent sexual side effects of finasteride for male pattern hair loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

Testosterone and erectile function: from basic research to a new clinical paradigm for managing men with androgen insufficiency and erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

Differential expression of 5 alpha-reductase isoenzymes in the human prostate and prostatic carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

The role of dihydrotestosterone in benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

The physiological role of androgens in penile erection: regulation of corpus cavernosum structure and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

Androgens play a pivotal role in maintaining penile tissue architecture and erection: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

Recent insights into androgen action on the anatomical and physiological substrate of penile erection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

5-alpha reductase inhibitors and erectile dysfunction: the connection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

Localization of 5alpha-reductase in the rat main olfactory bulb

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

Structural and biochemical properties of cloned and expressed human and rat steroid 5 alpha-reductases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

Human prostatic steroid 5α-reductase isoforms—A comparative study of selective inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

5α-reductase type 3 expression in human benign and malignant tissues: a comparative analysis during prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

Impact of medical treatments for benign prostatic hyperplasia on sexual function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

Finasteride in the treatment of men with frontal male pattern hair loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

Mechanism of salutary effects of finasteride on post-traumatic immune/inflammatory response: upregulation of estradiol synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

Anti-nociceptive and anti-inflammatory properties of 5alpha-reductase inhibitor finasteride in experimental animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

Finasteride-induced depression: new insights into possible pathomechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

An overview on 5alpha-reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

Effect of dutasteride on the risk of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

Dihydrotestosterone is the active androgen in the maintenance of nitric oxide-mediated penile erection in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

The Effects of Chronic 5‐Alpha‐Reductase Inhibitor (Dutasteride) Treatment on Rat Erectile Function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

An Old Problem with a New Cause-5 Alpha Reductase Inhibitors and Persistent Sexual Dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

Physician perceptions of sexual dysfunction related to benign prostatic hyperplasia (BPH) symptoms and sexual side effects related to BPH medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. The North American Finasteride Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.742885

10.1517/14740338.2013.742885

21 January 2018

Identifiers

DOI

1 reference

1 August 2017

1 reference